OR WAIT null SECS
December 12, 2019
Life science and healthcare business accelerator, Start Codon, and membership organization, One Nucleus, have partnered up to support the life science ecosystem in the United Kingdom.
Swiss-based specialist pharma R&D company, MetP Pharma, has been granted a Notice of Allowance from the Unites States Patent and Trademark Office (USPTO) for its patent titled, “Treatment of Demyelineating Diseases.”
Galderma, a Swiss-based dermatology company that the United States Food and Drug Administration (FDA) has granted breakthrough therapy designation to its investigational therapy, nemolizumab.
The biologic is a novel bone builder that has a dual effect of increasing bone formation and reducing bone loss.
December 05, 2019
A drug discovery company based in the United Kingdom, Lunac Therapeutics, has been awarded funding worth £3.14 million (US$4.11 million) under Innovate UK’s Biomedical Catalyst program.
BioMed X has announced the successful completion of its first joint research project in the fields of COPD and IPF that it had undertaken with Boehringer Ingelheim.
Data released by the Cell and Gene Therapy Catapult (CGT Catapult) have shown that demands for specialist skills and investment in the cell and gene therapy industry in the United Kingdom are set to increase in the near future.
CPI has partnered with ImmunoBiology (ImmBio) for the development of a heat-stabilized formulation of a mutli-antigen vaccine candidate against Pneumococcal diseases.
Iontas has entered into a collaboration agreement with Adaptate Biotherapeutics for the generation and optimization of antibodies for novel immune-oncology targets.
GE Healthcare Life Sciences and Guangzhou Development District Investment Promotion Bureau have signed an agreement to jointly establish a training center for biopharmaceutical professionals.